iPSC-based drug discovery for neurological mitochondrial disease: presentation of recent scientific data
Mitochondrial DNA (mtDNA) mutations frequently cause neurological diseases. Modeling of these defects has been difficult because of the challenges associated with engineering mtDNA. Patient-derived induced pluripotent stem cells (iPSCs) allow the development of innovative cellular models in a personalized approach.
During Targeting Mitochondria World Congress, Dr Alessandro Prigione from Max Delbrueck Center for Molecular Medicine, Germany will discuss the potential benefits of patient iPSCs for drug discovery of neurological mitochondrial diseases.
To access to the preliminary agenda, please click here.